We then provide a molecular basis of the Sema3A/neuropilin-1/TGF-β receptor type 1 (Sema3A/NRP1/TGF-βR1) signaling axis in GBM and propose that this signaling node is a key GSC regulator and a potential therapeutic target. This evidence concerns the gene TGFBR1 and glioblastoma.